205 related articles for article (PubMed ID: 31167814)
1. Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir.
Kosloski MP; Bow DAJ; Kikuchi R; Wang H; Kim EJ; Marsh K; Mensa F; Kort J; Liu W
J Pharmacol Exp Ther; 2019 Aug; 370(2):278-287. PubMed ID: 31167814
[TBL] [Abstract][Full Text] [Related]
2. Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.
Kosloski MP; Oberoi R; Wang S; Viani RM; Asatryan A; Hu B; Ding B; Qi X; Kim EJ; Mensa F; Kort J; Liu W
J Infect Dis; 2020 Jan; 221(2):223-231. PubMed ID: 31504702
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
4. Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study.
Kalluri HV; Kikuchi R; Coppola S; Schmidt J; Mohamed MF; Bow DAJ; Salem AH
Clin Transl Sci; 2021 Jan; 14(1):373-381. PubMed ID: 33048456
[TBL] [Abstract][Full Text] [Related]
5. Drug-Drug Interactions of Tacrolimus or Cyclosporine With Glecaprevir and Pibrentasvir in Healthy Subjects.
Kosloski MP; Zhao W; Li H; Pugatch D; Asatryan A; Kort J; Mensa FJ; Liu W
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):779-789. PubMed ID: 30861340
[TBL] [Abstract][Full Text] [Related]
6. Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
Ogasawara K; Wood-Horrall RN; Thomas M; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2021 Dec; 88(6):941-952. PubMed ID: 34477937
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers.
Lin CW; Dutta S; Zhao W; Asatryan A; Campbell A; Liu W
Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):81-90. PubMed ID: 28688001
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.
Flamm S; Reddy KR; Zadeikis N; Hassanein T; Bacon BR; Maieron A; Zeuzem S; Bourliere M; Calleja JL; Kosloski MP; Oberoi RK; Lin CW; Yu Y; Lovell S; Semizarov D; Mensa FJ
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):527-535.e6. PubMed ID: 30012435
[TBL] [Abstract][Full Text] [Related]
10. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
11. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
Ebner T; Ishiguro N; Taub ME
J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects.
Lin CW; Dutta S; Ding B; Wang T; Zadeikis N; Asatryan A; Kort J; Campbell A; Podsadecki T; Liu W
J Clin Pharmacol; 2017 Dec; 57(12):1616-1624. PubMed ID: 28800195
[TBL] [Abstract][Full Text] [Related]
13. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
14. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
[TBL] [Abstract][Full Text] [Related]
15. Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.
Oshida K; Shimamura M; Seya K; Ando A; Miyamoto Y
Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):117-128. PubMed ID: 26961540
[TBL] [Abstract][Full Text] [Related]
16. Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3.
Heinig R; Fricke R; Wertz S; Nagelschmitz J; Loewen S
Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):803-815. PubMed ID: 36029368
[TBL] [Abstract][Full Text] [Related]
17. Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects.
Kosloski MP; Zhao W; Marbury TC; Preston RA; Collins MG; Pugatch D; Mensa F; Kort J; Liu W
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263061
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment.
Kosloski MP; Wang H; Pugatch D; Mensa FJ; Gane E; Lawitz E; Marbury TC; Preston RA; Kort J; Liu W
Eur J Clin Pharmacol; 2019 Feb; 75(2):217-226. PubMed ID: 30341499
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects.
Yamazaki T; Desai A; Goldwater R; Han D; Lasseter KC; Howieson C; Akhtar S; Kowalski D; Lademacher C; Rammelsberg D; Townsend R
Clin Pharmacol Drug Dev; 2017 Jan; 6(1):66-75. PubMed ID: 27273004
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions.
Zhang Q; Zhang Y; Boer J; Shi JG; Hu P; Diamond S; Yeleswaram S
Drug Metab Dispos; 2017 Jun; 45(6):612-623. PubMed ID: 28283500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
